Repligen | RGEN - Current Liabilities



Repligen reported $152M in Current Liabilities for its fiscal quarter ending in March of 2025.


Current Liabilities Change Date
Agilent USD 1.89B 120M Jul/2025
Align Technology USD 2B 4.54M Jun/2025
Bio Techne USD 175.85M 6.64M Jun/2025
BioMarin Pharmaceutical USD 684.25M 56.03M Jun/2025
Bristol-Myers Squibb USD 27.53B 3.46B Jun/2025
Bruker USD 1.35B 2.5M Jun/2025
Charles River Laboratories USD 1.08B 29.38M Jun/2025
Danaher USD 6.79B 147M Jun/2025
Dentsply International USD 1.17B 627M Jun/2025
Exact Sciences USD 521.93M 19.47M Jun/2025
General Electric Aerospace USD 36.47B 1.52B Jun/2025
Henry Schein USD 3.01B 90M Jun/2025
Illumina USD 1.46B 21M Jun/2025
IQVIA Holdings USD 7.57B 393M Jun/2025
Mettler Toledo International USD 1.11B 42.8M Jun/2025
Myriad Genetics USD 151.1M 13M Mar/2025
Pfizer USD 37.73B 1.27B Jun/2025
Repligen USD 152M 25.21M Mar/2025
Revvity USD 671.81M 23.63M Jun/2025
Standard Biotools USD 98.02M 32.13M Jun/2025
Thermo Fisher Scientific USD 12.72B 456M Jun/2025
Waters USD 1.02B 55.16M Jun/2025
West Pharmaceutical Services USD 604.6M 77.9M Jun/2025